Samtica (Abiraterone) 250 mg
Samtica 250 mg (Abiraterone Acetate) is a hormone therapy used to treat prostate cancer.
Manufacturer: Samarth Life Sciences (India). Samtica is a cost-effective generic version of the brand-name drug Zytiga.
Mechanism of Action ("Fuel Cut-Off"):
Prostate cancer cells rely on testosterone to grow. While standard therapies stop testosterone production in the testes, Abiraterone inhibits the CYP17 enzyme, blocking testosterone production everywhere in the body: testes, adrenal glands, and the tumor tissue itself. By cutting off the fuel supply, it stops tumor progression.
✅ Key Benefit: Significantly extends survival rates and lowers PSA levels in metastatic patients.
Indicated for metastatic prostate cancer (mCRPC and mHSPC):
- 🎗️ Castration-Resistant Prostate Cancer: When the disease progresses despite standard androgen deprivation therapy (ADT).
- 🎗️ High-Risk Castration-Sensitive Prostate Cancer: Used in newly diagnosed metastatic cases for better control.
Packaging: Bottle of 120 Tablets (250 mg each). Supply for 1 month.
⚠️ ADMINISTRATION PROTOCOL:
- 💊 Standard Dose: 1,000 mg (4 tablets) taken once daily.
- 🍽️ EMPTY STOMACH ONLY! No food should be consumed for at least 2 hours before and 1 hour after taking the tablets. Taking it with food can lead to dangerous overdose levels.
- 💊 Combination Therapy: Must be taken with low-dose Prednisone/Prednisolone to prevent hypertension and fluid retention.
- Severe hepatic (liver) impairment.
- Women who are or may become pregnant should not handle the tablets without protection.
- Hypersensitivity to the active substance.
Common side effects to monitor:
- 🦵 Fluid Retention: Swelling in legs or feet (Peripheral edema).
- ❤️ Hypertension & Hypokalemia: High blood pressure and low potassium levels (managed by taking Prednisone).
- Elevated liver enzymes (ALT/AST). Regular blood tests are required.
Similar products
What Customers Say
No reviews yet
Your review can be the first!